• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home 2MM Trial Briefs

ADCE-D01 showed a 30% objective response rate in topline phase 1 results for previously treated advanced soft tissue sarcoma

by2 Minute MedicineandReviewed by Andrew Cheung, MD MBA (McMaster University)
November 20, 2026
in 2MM Trial Briefs, Hematology, Oncology, Pharma
Reading Time: 2 mins read
Soft tissue sarcoma collage: arm muscles with an oval outlined in dotted teal, brass calipers and a folded surgical cap
Share on FacebookShare on TwitterShare on LinkedIn

1. ADCE-D01, an antibody-drug conjugate (ADC), produced a 30% objective response rate and 85% disease control rate on an every-2-week (every 2 weeks [Q2W]) schedule.

2. In 47 adults, Q2W treatment caused dose reductions in 10% of patients and no discontinuations for side effects; severe neutropenia occurred in 14% with prophylactic granulocyte colony-stimulating factor (G-CSF).

Evidence Rating Level: 2 (Good)

2MM Brief: Adcendo ApS reported initial, not yet peer-reviewed results for ADCE-D01, an ADC, in previously treated adults with advanced soft tissue sarcoma (STS). The data were presented in a late-breaking oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. The ongoing ADCElerate1 trial (NCT06797999) is a first-in-human, phase 1/phase 2, multicenter, open-label, dose-escalation and expansion study of ADCE-D01 monotherapy in patients with metastatic and/or unresectable STS. The company reported results for 47 adults with 17 STS subtypes who had received prior systemic treatment, including chemotherapy and targeted agents; the median number of prior lines was two, with a range of 1-4. The first 18 patients received weekly dosing, and the next 29 received dosing Q2W. Among 27 response-evaluable patients receiving Q2W treatment, 8 had a partial response (PR), corresponding to a 30% objective response rate; 5 responses were confirmed and 3 were currently unconfirmed. The disease control rate was 85% (23/27). Median follow-up was 3.4 months, median duration of response had not been reached, and all responses were ongoing at data cutoff. The most common treatment-related side effects on the Q2W schedule were low-grade nausea (59%), infusion-related reactions (41%), tiredness (38%), hair loss (35%) and neutropenia (31%). Dose reduction occurred in 10% of patients, and no patients discontinued treatment for side effects. With prophylactic G-CSF, severe neutropenia occurred in 14% (3/22), compared with 43% (3/7) without G-CSF. The maximum tolerated dose (MTD) had not been reached, and no cases of interstitial lung disease, febrile neutropenia or stomatitis were observed. Confidence intervals and P values were not reported. Limitations include the small, noncomparative, open-label, ongoing study, short follow-up, unconfirmed responses and results that have not been peer reviewed. These findings suggest antitumor activity and manageable reported tolerability for ADCE-D01 in this early study, but further follow-up and comparative data are needed.

Citation

© 2026 2 Minute Medicine, Inc. All rights reserved. No part of this article may be reproduced, distributed or transmitted in any form or by any means without the prior written permission of 2 Minute Medicine, Inc. To license this content, contact 2 Minute Medicine, Inc. This article is for informational and educational purposes only; it is not medical advice and does not replace the judgment of a qualified healthcare professional.
Image: © 2 Minute Medicine

RELATED REPORTS

Sacituzumab tirumotecan improved progression-free and overall survival versus chemotherapy in previously treated endometrial cancer

Tisotumab Vedotin as Second or Third-Line Therapy for Recurrent Cervical Cancer

Tags: ADCE-D01ADCElerate1antibody drug conjugateSoft Tissue Sarcoma
Previous Post

Less social media usage is associated with improved internalizing symptoms in high-risk young adults.

RelatedReports

The image illustrates antibodies and a pill, representing immunotherapy and steroid treatments in oncology, with visual elements suggesting timing of administration.
2MM Trial Briefs

Sacituzumab tirumotecan improved progression-free and overall survival versus chemotherapy in previously treated endometrial cancer

October 29, 2026
Cervical cancer collage: a teal and white awareness ribbon, a vaccine vial, a glass slide, white lilies and a clinic gown
Oncology

Tisotumab Vedotin as Second or Third-Line Therapy for Recurrent Cervical Cancer

July 15, 2024
Stereotactic radiosurgery promising for patients with multiple brain metastases
Oncology

Concurrent stereotactic radiation with antibody-drug conjugates in the treatment of brain metastases is associated with a greater risk of symptomatic radiation necrosis

November 13, 2023
Chronic Disease

United States-based chemotherapy regimen for Ewing sarcoma is more effective and safer than the standard European regimen

November 9, 2022
✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • ADCE-D01 showed a 30% objective response rate in topline phase 1 results for previously treated advanced soft tissue sarcoma
  • Less social media usage is associated with improved internalizing symptoms in high-risk young adults.
  • AI cardiac MRI analysis marginally outperforms clinicians in predicting all-cause mortality
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.